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Abstract  
 The present review study reviewed the literature for the possible 
therapeutic roles of aspirin against tumors. Aspirin has various therapeutic 
properties among which is the anti-inflammatory property. Epidemiological 
studies have proved the efficacy of long term use of aspirin in reducing the 
incidence of colorectal cancer by up to 30%, and the cancer risk as well. 
Although no exact mechanism has been entirely proposed so far to explain the 
antineoplastic effect of aspirin against cancer, two mechanisms have been 
under focus, the first is related to its anti-inflammatory properties which are 
thought to suppress the inflammatory mediators and to inhibit carcinogenic 
mechanisms, and the other mechanism is through the deactivation of COX2. 
We would like to raise the possibility for aspirin to be regularly involved in 
preventive mechanisms.
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Introduction  
An overview of aspirin 
The history of aspirin synthesis and production has begun since 
1897 when Bayer manufactured it (Jack, 1997). Aspirin has a simple chemical 
structure composed of a benzene ring attaching to an acetyl group and a 
carboxylic acid group  (Logan, 2007). Aspirin is also called acetylsalicylic 
acid and it is one of the members in the group called non-steroidal anti-
inflammatory drugs (NSAIDs) (Vane and Botting, 2003). Aspirin has various 
therapeutic properties including analgesic, anti-pyretic, anti-thrombotic and 
anti-inflammatory (Poindexter, 2015). 
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Overview of cancer 
The definition of cancer implies the presence of malignant neoplasia 
that are characterized by uncontrolled growth of cells which usually have the 
ability to invade local or in other sites of the body. Cancers are classified 
according to the type of tissue or the primary site in which they are originated 
(Taber's Cyclopedic Medical Dictionary, 2013). 
Epidemiological studies have pointed to the presence of 1.7 million 
new cancer cases in the United States in 2014, and the incidence of cancer is 
about 460 per 100,000 persons (Howlader et al., 2014). The most prevalent 
cancers among humans include lung, colorectal, prostate, and breast cancer 
(Siegel et al., 2013).  
In the USA, cancer is in the second rank in causing death, and accounts 
for 25% deaths (Siegel et al., 2013). It has been reported that lung cancer, 
colorectal cancer, breast cancer, and prostate cancer are the most prevalent 
types of cancers (Howlader et al., 2014). 
 
Aspirin and colorectal cancer (CRC) 
According to the study of Burn and  Sheth (2016), colorectal cancer 
(CRC) is considered among the most prevalent cancers in the Western 
countries and the second leading cause of mortality  due to cancer in the UK 
and USA. The authors also expressed their views that systematic  intake of 
aspirin has the ability to lower several cancer parameters including incidence, 
recurrence, metastasis and mortality.  
Aspirin has been believed to act as chemopreventative treatment 
because authors showed its ability to lower the development of precancerous 
adenomas and CRC (Flossmann and Rothwell 2007; Cole et al., 2009). 
Cancer studies have shown that the use of aspirin to be associated with 
risk reduction of developing adenoma by 30% and the development of CRC 
by 26% (Cole et al., 2009; Cooper et al., 2010). These findings have been 
confirmed in vivo and in vitro on cancer cells, tumor tissue microenvironment 
and cytokines (Garcia-Albeniz and Chan, 2011).  
According to Rothwell et al (2012), the daily intake of aspirin lowers 
overall cancer problems in cancer patients. The study of Gamba et al (2013) 
demonstrated the low doses intake of aspirin continuously to be associated 
with reduced incidence of melanoma among women.  Other studies have 
indicated that patients who take aspirin have low prevalence of colorectal, 
esophageal, pancreatic, and lung cancer compared with who do not (Rothwell 
et al., 2012). 
 
Aspirin and COX-2 
The mechanism by which aspirin mediates its action against cancer 
cells is thought to be through the inhibition of cyclo-oxygenase enzymes 
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(COX-1 and COX-2) which work to catalyze tissue-specific signaling lipids. 
Aspirin has the ability to inactivate these enzymes by acetylating serine 
residues (Thun, Jacobs, and Patrono, 2012).   
The expression of COX-2 was reported in various tissues and can be 
induced in other tissues through inflammatory processes, wound healing and 
tumors. It has been shown that aspirin counteracts tumorigenesis  through the 
action in the  COX-2 pathway (Sostres, Gargallo , and Lanas, 2014). Another 
study by Chan et al (2007) showed that aspirin lowers the risk of CRC among 
persons who upregulates the expression of COX-2 in comparison with persons 
who do not.  
It has been reported that the inhibition of  COX-2 activity in nucleated 
cells requires high doses of aspirin (>2,000 mg daily) (Chan et al., 2007; 
Sostres, Gargallo , and Lanas, 2014). Furthermore, it has been demonstrated 
that if the genes of either COX1 or COX2 are deleted, the formation of 
ntestinal polyp in a mouse model will be reduced (Sostres, Gargallo , and 
Lanas, 2014).  
Several studies have focused on the mortality among patients with 
CRC and its relation with the use of aspirin. These studies have shown that the 
risk for CRC death was reduced among patients who used aspirin 75-1200 mg 
daily for at least 1 year (Farrell  et al., 1991; Petoet al., 1988; Rothwell et al., 
2010). 
 
 
The role of aspirin in targeting inflammation to counteract carcinogenesis 
Todoric et al (2016) conducted a study in view of some considerations 
among which is the association of inflammation with both the development 
and malignant progression of most cancers. There are extrinsic and intrinsic 
factors, due to inflammation, can stimulate cancer in general. The intake of 
aspirin can counteract these mechanisms and reduce the initiating of 
carcinogenesis.   
According to Chan et al (2012), no exact mechanism has been 
proposed to explain its effects against carcinogenesis, but it is thought that this 
may due to its modulating role of inflammatory reactions and direct effect on 
tumor cells. 
Aspirin can exert its anti-neoplastic effects through inhibiting 
prostaglandin G/H-synthase 2 (PGHS2) transcription, and prevention the 
conversion of PGHS2 and COX2 from arachidonic acid to potentially tumour-
inducing prostaglandins. Aspirin can also decrease the expression of Sp1, Sp3 
and Sp4 transcription factors, and vascular endothelial growth factor (VEGF), 
and by thus lowers tumor cell growth (Bae et al., 2003). According to the study 
of Liao et al (2012),  aspirin has been only of beneficial effect in CRCs with a 
mutated, rather than wild-type PIK3CA gene which may demonstrate the 
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effects of aspirin from other non-steroids. Proposing that salicylic acid has the 
antineoplastic property in aspirin, then  dietary intake could be therapeutic 
(Paterson et al., 2007).  
 
Conclusion 
In this review study, we reviewed the literature for the use of aspirin 
as anti-cancer agent. May studies have shown its efficacy in reducing the 
development and incidence of cancers in general and particularly, the CRC. 
Suggested mechanisms rotate on the axis of inflammation and the inhibition 
of COX2. 
 
References: 
1. Bae Y. et al (2003). Molecular ordering of ROS production, 
mitochondrial changes, and caspase activation during sodium 
salicylate-induced apoptosis Free Radical Biology and Medicine, 
34(4): 434– 442. 
2. Chan AT, Ogino S, Fuchs CS (2007). Aspirin and the risk of colorectal 
cancer in relation to the expression of COX-2. N Engl J Med, 
356(21):2131-42. 
3. Chan, A. T., N. Arber, J. Burn, W. K. Chia, P. Elwood, M. A. Hull, R. 
F. Logan, P. M. Rothwell, K. Schror and J. A. Baron (2012). Aspirin 
in the chemoprevention of colorectal neoplasia: an overview. Cancer 
Prev Res (Phila) 5(2): 164-178. 
4. Cole, B. F., R. F. Logan, S. Halabi, R. Benamouzig, R. S. Sandler, M. 
J. Grainge, S. Chaussade and J. A. Baron (2009). Aspirin for the 
chemoprevention of colorectal adenomas: meta-analysis of the 
randomized trials. J Natl Cancer Inst 101(4): 256-266. 
5. Cooper, K., H. Squires, C. Carroll, D. Papaioannou, A. Booth, R. F. 
Logan, C. Maguire, D. Hind and P. Tappenden (2010). 
Chemoprevention of colorectal cancer: systematic review and 
economic evaluation. Health Technol Assess 14(32): 1-206. 
6. Farrell B, Godwin J, Richards S, Warlow C (1991). The United 
Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final 
results. J Neurol Neurosurg Psychiatry, 54:1044-54.  
7. Flossmann, E. and P. M. Rothwell (2007). Effect of aspirin on long-
term risk of colorectal cancer: consistent evidence from randomised 
and observational studies. Lancet 369(9573): 1603-1613. 
European Scientific Journal December 2016 edition vol.12, No.36 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
434 
8. Gamba, C. A., Swetter, S. M., Stefanick, M. L., Kubo, J., Desai, M., 
Spaunhurst, K. M., Sinha, A. A., Asgari, M. M., Sturgeon, S., and 
Tang, J. Y. (2013). Aspirin is associated with lower melanoma risk 
among postmenopausal Caucasian women: the Women's Health 
Initiative.  Cancer 119, 1562-1569. 
9. Garcia-Albeniz, X. and A. T. Chan (2011). Aspirin for the prevention 
of colorectal cancer. Best Pract Res Clin Gastroenterol 25(4-5): 461-
472. 
10. Howlader, N, Noone, AM, Krapcho, M, et al (2014). SEER Cancer 
Statistics Review, 1975-2011. Bethesda, MD: National Cancer 
Institute, PMID: None. 
11. Jack DB (1997). One hundred years of aspirin. Lancet, 350:437–39. 
12. Jelena Todoric, Laura Antonucci, Michael Karin (2016). Targeting 
Inflammation in Cancer Prevention and Therapy. Cancer Prev Res 
November 10 2016 DOI: 10.1158/1940-6207.CAPR-16-0209. 
13. John Burn,  Harsh Sheth (2016). The role of aspirin in preventing 
colorectal cancer. Br Med Bull, 119 (1): 17-
24.doi: 10.1093/bmb/ldw028. 
14. Kevin Michael Poindexter (2015). Regulation of anti-proliferation in 
melanoma and breast cancer cells by small molecule phytochemicals 
and their derivatives. Ph. D dissertation. University of California, 
Berkeley. 
15. Liao, X. et al (2012). Aspirin Use, Tumor PIK3CA Mutation, and 
Colorectal-Cancer Survival. New England Journal of Medicine, 
367(17): 1596-1606. 
16. Paterson TJ, Baxter G, Lawrence J, Duthie G (2006). Is there a role for 
dietary salicylates in health? Proc Nutr Soc, 65: 93–96. 
17. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et 
al (1988). Randomised trial of prophylactic daily aspirin in British 
male doctors. Br Med J (Clin Res Ed), 296:313-6.  
18. Richard Logan (2007). Commentary: Preventing colorectal cancer 
with aspirin—what next. International Journal of Epidemiology, 
36:960–962. 
19. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, 
et al (2012). Long-term effect of aspirin on colorectal cancer incidence 
European Scientific Journal December 2016 edition vol.12, No.36 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 
435 
and mortality: 20-year follow-up of five randomised trials. Lancet, 
376:1741-50.  
20. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. 
P., and Meade, T. W. (2011). Effect of daily aspirin on long-term risk 
of death due to cancer: analysis of individual patient data from 
randomized trials. Lancet 377, 31-41. 
21. Rothwell, P. M., Price, J. F., Fowkes, F. G., Zanchetti, A., Roncaglioni, 
M. C., Tognoni, G., Lee, R., Belch, J. F., Wilson, M., Mehta, Z., and 
Meade, T. W. (2012). Short-term effects of daily aspirin on cancer 
incidence, mortality, and non-vascular death: analysis of the time 
course of risks and benefits in 51 randomised controlled trials. Lancet 
379, 1602-1612. 
22. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013, CA 
Cancer J Clin, 63(1):11-30. PMID: 23335087. 
23. Sostres C, Gargallo CJ, Lanas A (2014). Aspirin, cyclooxygenase 
inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther 
6;5(1):40-9. 
24. Taber's Cyclopedic Medical Dictionary (2013). Charlottesville, VA: 
Unbound Medicine, Inc. PMID: None. 
25. Thun MJ, Jacobs EJ, Patrono C (2012). The role of aspirin in cancer 
prevention. Nat Rev Clin Oncol, 9(5):259-67.  
26. Vane, J. R., Botting, R. M (2003). The mechanism of action of aspirin 
Thromb. Res. 110, 255-258. 
  
